A CORRELAÇÃO ENTRE O USO DE ESCITALOPRAM EM IDOSOS E O PROLONGAMENTO DO INTERVALO QT.
Keywords:
Escitalopram, QT prolongation, Elderly, ArrhythmiaAbstract
To achieve the objective of verifying whether there is a correlation between the use of escitalopram in the elderly and QT prolongation, a search was carried out in Pubmed, Scielo and Lilacs. The selected studies were evaluated using the Newcastle-Ottawa scale to assesses study quality. The studies indicate that the link between escitalopram use and serious arrhythmia is weak despite FDA recommendations. The risk of arrhythmia and mortality associated with escitalopram also decreased over time. Cardiac comorbidities increase the risk of QT prolongation and mortality, and modifiable risk factors like hypokalemia and drug interactions should be addressed in at-risk individuals. Healthcare providers face a difficult decision regarding dosage restrictions and medication switching, taking into account escitalopram's effectiveness and tolerability. More research and awareness are needed to optimize antidepressant therapy for cardiac safety.
Downloads
References
Rao N. The Clinical Pharmacokinetics of Escitalopram. Clin Pharmacokinet. 2007;46(4):281-90. doi: https://doi.org/10.2165/00003088-200746040-00002
Croom KF, Plosker GL. Escitalopram. PharmacoEconomics. 2003;21(16):1185-209. doi: https://doi.org/10.2165/00019053-200321160-00004
Cubeddu L. Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias. Curr Cardiol Rev. 2016;12(2):141-54. doi: https://doi.org/10.2174/1573403X12666160301120217
Beach SR, Celano CM, Sugrue AM, Adams C, Ackerman MJ, Noseworthy PA, et al. QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update. Psychosomatics. 2018;59(2):105-22. doi: https://doi.org/10.1016/j.psym.2017.10.009
Tseng PT, Lee Y, Lin YE, Lin PY. Low-dose escitalopram for 2 days associated with corrected QT interval prolongation in a middle-aged woman: a case report and literature review. Gen Hosp Psychiatry. 2012;34(2):210.e13-210.e15. doi: https://doi.org/10.1016/j.genhosppsych.2011.10.005
Schulz P. Biological clocks and the practice of psychiatry. Chronobiol Psychiatry. 2007;9(3):237-55. doi: https://doi.org/10.31887/DCNS.2007.9.3/pschulz
Kim Y, Kim A, Chung JY. Population pharmacokinetic/pharmacodynamic modeling of delayed effect of escitalopram-induced QT prolongation. J Affect Disord. 2021; 285:120-6. doi: https://doi.org/10.1016/j.jad.2021.02.048
Chung H, Kim A, Lim KS, Park SI, Yu KS, Yoon SH, et al. Pharmacokinetics and effect on the corrected QT interval of single-dose escitalopram in healthy elderly compared with younger adults. Int Clin Psychopharmacol. 2017;32(1):20-6. doi: https://doi.org/10.1097/YIC.0000000000000149
Ojero-Senard A, Benevent J, Bondon-Guitton E, Durrieu G, Chebane L, Araujo M, et al. A comparative study of QT prolongation with serotonin reuptake inhibitors. Psychopharmacology. 2017;234(20):3075-81. doi: https://doi.org/10.1007/s00213-017-4685-7
Assimon MM, Brookhart MA, Flythe JE. Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis. J Am Soc Nephrol. 2019;30(4):611-23. doi: https://doi.org/10.1681/ASN.2018101032
Hasnain M, Howland R, Vieweg W. Escitalopram and QTc prolongation. J Psychiatry Amp Neurosci. 2013;38(4):E11. doi: https://doi.org/10.1503/jpn.130055
Chastang A, Renet S, Corny J, Beaussier H, Petre A, Lillo-Lelouet A, et al. Impact of hospital pharmacist interventions on the combination of citalopram or escitalopram with other QT-prolonging drugs. Int J Clin Pharm. 2019 jan 4; 41(1):42-8. doi: https://doi.org/10.1007/s11096-018-0724-7
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiology. 2010 jul 22; 25(9):603-5. doi: https://doi.org/10.1007/s10654-010-9491-z
Crépeau-Gendron G, Brown HK, Shorey C, Madan R, Szabuniewicz C, Koh S, et al. Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting. J Affect Disord. 2019 May; 250:341-5. doi: https://doi.org/10.1016/j.jad.2019.02.060
U.S. Food and Drug Administration. Drug Safety and Availability. https://www.fda.gov/drugs/drugsafety
Aakjær M, Werther SK, De Bruin ML, Andersen M. Serious arrhythmia in initiators of citalopram, escitalopram, and other selective serotonin reuptake inhibitors: A population‐based cohort study in older adults. Clin Transl Sci. 2022 jun 22. doi: https://doi.org/10.1111/cts.13319
ANVISA. Agência Nacional de Vigilância Sanitária. Notificações de farmacovigilância. https://www.gov.br/anvisa/pt-br/acessoainformacao/dadosabertos/informacoes-analiticas/notificacoes-de-farmacovigilancia
Mota DM, Vigo Á, Kuchenbecker RD. Reações adversas a medicamentos no sistema de farmacovigilância do Brasil, 2008 a 2013: estudo descritivo. Cad Saude Publica. 2019;35(8). doi: https://doi.org/10.1590/0102-311x00148818
Qirjazi E, McArthur E, Nash DM, Dixon SN, Weir MA, Vasudev A, et al. Risk of Ventricular Arrhythmia with Citalopram and Escitalopram: A Population-Based Study. PLOS ONE. 2016 ago 11;11(8):e0160768. doi: https://doi.org/10.1371/journal.pone.0160768
Fung KW, Baye F, Kapusnik-Uner J, McDonald CJ. Using Medicare Data to Assess the Proarrhythmic Risk of Non-Cardiac Treatment Drugs that Prolong the QT Interval in Older Adults: An Observational Cohort Study. Drugs Real World Outcomes. 2021 fev 10;8(2):173-85. doi: https://doi.org/10.1007/s40801-021-00230-1
Shah SR, Park K, Alweis R. Long QT Syndrome: A Comprehensive Review of the Literature and Current Evidence. Curr Probl Cardiol. 2019 mar; 44(3):92-106. doi: https://doi.org/10.1016/j.cpcardiol.2018.04.002
Trinkley KE, Lee Page R, Lien H, Yamanouye K, Tisdale JE. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin [Internet]. 2013 set 23 [citado 2023 jun 10];29(12):1719-26. doi: https://doi.org/10.1185/03007995.2013.840568
Seiler F, von Hardenberg A, Böhm M, Bals R, Maack C. Kardiopulmonale Komorbiditäten. DMW DTSCH Med Wochenschr [Internet]. 2016 fev 17 [citado 2023 jun 10]; 141(04):275-84. doi: https://doi.org/10.1055/s-0041-108687
Downloads
Published
Issue
Section
License
Os artigos submetidos à revista Colloquium Vitae estão licenciados conforme CC BY-NC-ND. Para mais informações sobre essa forma de Licenciamento, consulte: http://creativecommons.org/licenses/by-nc-nd/4.0/.
A disponibilização é gratuita na Internet, para que os usuários possam ler, fazer download, copiar, distribuir, imprimir, pesquisar ou referenciar o texto integral dos documentos, processá-los para indexação, utilizá-los como dados de entrada de programas para softwares, ou usá-los para qualquer outro propósito legal, sem barreira financeira, legal ou técnica.